Apelin vs Adrenomedullin
Side-by-Side Comparison
| Attribute | Apelin | Adrenomedullin |
|---|---|---|
| Category | Cardiovascular / Vasoactive | Cardiovascular / Vasoactive |
| Mechanism | Apelin binds to the APJ receptor (APLNR), a Gi-coupled GPCR. In the cardiovascular system, apelin/APJ signaling produces positive inotropy via phospholipase C activation and increased intracellular... | Adrenomedullin signals through the calcitonin receptor-like receptor (CLR) complexed with receptor activity-modifying protein 2 or 3 (RAMP2/RAMP3), forming the AM1 and AM2 receptors respectively. |
| Evidence Rating | D — Preclinical / Early Research | D — Biomarker / Early Research |
| Clinical Status | Preclinical and early-phase clinical investigation. No approved therapeutic indication. | Research stage. MR-proADM used as prognostic biomarker in sepsis and heart failure. No approved therapeutic use of adrenomedullin peptide. |
| Safety Profile | No human safety data from controlled clinical trials; Hypotension is the expected pharmacological effect and primary theoretical risk | No human safety data from controlled therapeutic trials; Experimental IV infusion in healthy volunteers caused hypotension and reflex tachycardia |
| Route | Intravenous infusion (research only) | Intravenous infusion (research only) |
| Dose Range | 30–300 pmol/kg/min ([Pyr1]apelin-13 in human research) | 10–50 ng/kg/min in human physiological studies |
| Frequency | Continuous | Continuous or bolus infusion |
| Molecular Weight | N/A | ~6028 g/mol |
| Half-Life | <5 minutes (circulating) | ~22 minutes (plasma) |
Overview
Apelin and Adrenomedullin are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
Apelin — Mechanism & Evidence
Apelin is an endogenous peptide ligand for the APJ receptor (APLNR), existing in multiple bioactive forms including apelin-13, apelin-17, and apelin-36 derived from a 77-amino-acid preproapelin precursor. It plays important roles in cardiovascular regulation, fluid homeostasis, and cardiac inotropy. All forms remain in preclinical or early clinical investigation with no approved therapeutic applications.
Key claims: Apelin produces positive inotropy without increasing oxygen demand; Apelin levels are reduced in heart failure; Apelin/APJ axis regulates fluid homeostasis.
Adrenomedullin — Mechanism & Evidence
Adrenomedullin is a 52-amino-acid vasodilatory peptide (MW ~6028 g/mol) originally isolated from human pheochromocytoma tissue. It is widely expressed in the cardiovascular system, lungs, kidneys, and adrenal glands, with potent vasodilatory, natriuretic, and cardioprotective properties. It is currently investigated as a biomarker (MR-proADM) for sepsis and heart failure prognosis, with no approved therapeutic use of the peptide itself.
Key claims: MR-proADM is a strong prognostic biomarker in sepsis; MR-proADM predicts mortality in acute heart failure; Adrenomedullin has potent vasodilatory effects in humans.
Shared Research Applications
Both peptides are studied for: Cardiovascular Research.
Apelin is also researched for: Heart Failure Research.
Adrenomedullin is also researched for: Sepsis Prognostication, Heart Failure Biomarker.
Safety Considerations
Apelin: No human safety data from controlled clinical trials Hypotension is the expected pharmacological effect and primary theoretical risk Potential effects on fluid balance due to vasopressin antagonism
Adrenomedullin: No human safety data from controlled therapeutic trials Experimental IV infusion in healthy volunteers caused hypotension and reflex tachycardia Theoretical risk of excessive vasodilation and hemodynamic instability
